drugset
drugset / Trial / NCT05293912

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

NCT05293912 ↗

Phase 1 Terminated 2 enrolled Hangzhou Sumgen Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase Ia/Ib, first-in-Human, open-Label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of SG2501 in subjects with relapsed or refractory hematological malignancies and lymphoma.

Timeline

Start
2023-03-03
Primary completion
2023-06-30
Completion
2023-06-30

Outcome

Outcome not reported

Stopped: “Adjustment of clinical development plan”

Drugs

EvaluationDrugModalityDoseRoute
Subject SG2501 Unknown 0.01 mg/kg Intravenous
Subject SG2501 Unknown 0.03 mg/kg Intravenous
Subject SG2501 Unknown 0.1 mg/kg Intravenous
Subject SG2501 Unknown 0.3 mg/kg Intravenous
Subject SG2501 Unknown 1 mg/kg Intravenous
Subject SG2501 Unknown 2 mg/kg Intravenous
Subject SG2501 Unknown 4 mg/kg Intravenous
Subject SG2501 Unknown 6 mg/kg Intravenous

Indications

lymphoma